This session will focus on primary prevention of Atherosclerotic Cardiovascular Disease (ASCVD) by examining female sex-specific cardiovascular risk factors at each stage of life. Lipids are impacted during normal hormonal changes throughout a woman's life cycle- during adolescence, pre-pregnancy, pregnancy, pre- and perimenopause, menopause, and at older ages. ASCVD remains to be the number one cause of women’s death in the United States. Missed or delayed diagnosis, and undertreatment contributes to ASCVD such as elevated Lipoprotein (a) and Familial Hypercholesterolemia. Women’s cardiovascular rates are increasing among younger women <55 years as well as an increase suboptimal cardiovascular health during pregnancy. There is an increase in metabolic syndrome leading to prevalence of dyslipidemias. Younger women are less likely to be treated less and to achieving therapeutic targets. Previous guidelines acknowledge sex-specific risk enhancing factors for lipid management in women for Cardiovascular prevention. There is a continued need for sex-specific guidelines for evaluation and management of lipids. Future research should focus on increasing enrollment of women in lipid trials. This session is to enhance clinical practice in the management of cardiovascular/cardiometabolic health of women across the lifespan.